Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer's PF-0496582, AbbVie's upadacitinib and Incyte's topical ruxolitinib have the most potential upside if approved
Read MoreWith no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights
Read MoreThe majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights
Read MoreInternational psychiatric watchdog group Citizens Commission on Human Rights (CCHR), an American civil rights leader and South African Khoisan royalty join forces at Cape Town rally to demand the World Psychiatric Association put an end to the potentially lethal drugging of South African children.
Read MoreSponsors partner with SCDAA for an event to benefit research, treatment, support services and programs for members of the sickle cell community nationwide.
Read MorePfizer as one of the global leading originators has extended operations with Media-Soft Pharmacentric Solutions. Pfizer has gone live with the global most flexible Bookvision CLM and Sales Vision CRM solution for pharmaceuticals.
Read MoreThe report provides a comprehensive analysis of market size of global and Latin America animal health care industry, market segmentation of Latin America animal health care industry by pharmaceuticals, vaccines and medical feeds.
Read MoreReimbursement Intelligence, the New Jersey-based market-research firm helping biopharma, medical device and diagnostic firms succeed in managed markets, today announced how payers predict the impact of Pfizer's radical strategy to stay in favor of
Read MoreCryerHealth, LLC, a boutique healthcare consulting firm committed to creating patient-centric solutions to health and healthcare delivery challenges, announced its sponsorship of the 5th Annual Rare Disease Leadership Summit.
Read More